HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation

• Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN™ AI as a globally recognized healthcare AI platform
• The broader 2026 International Prix Galien nominee field includes innovations from many of the world's leading pharmaceutical, biotechnology and medical technology companies, including AstraZeneca, Merck & Co. (MSD), Johnson & Johnson, Pfizer, Sanofi, Regeneron, Roche, Novo Nordisk, Gilead Sciences, Vertex Pharmaceuticals, Medtronic and Edwards Lifesciences, among others.
• DARWEN™ is designed to transform complex clinical information into structured, traceable intelligence, helping to identify patients who may otherwise be missed and accelerating clinical research and real-world evidence generation.
• HEALWELL has integrated DARWEN™ across its broader healthcare technology ecosystem, including Orion Health, creating the potential to leverage common AI intellectual property across multiple products, diseases, customers, health systems and geographies at global scale.

Toronto, Ontario--(Newsfile Corp. - August 19, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce that its subsidiary, Pentavere Research Group ("Pentavere"), developer of DARWEN™ AI, has been nominated for the 2026 International Prix Galien Award in the Best Startup category.

The nomination represents a significant progression for Pentavere following its receipt of the 2024 Prix Galien USA Award for Best Digital Health Startup. Unlike national Prix Galien competitions, the International Prix Galien is held every two years and brings together innovations that have already earned Prix Galien recognition in national and regional competitions around the world. The Galien Foundation describes the International Prix Galien as its global "best-of-the-best" competition, making Pentavere's nomination an important independent validation of DARWEN™ AI and HEALWELL's broader artificial intelligence strategy.

The International Prix Galien nomination represents another layer of external validation for HEALWELL's healthcare AI platform. Pentavere first earned international recognition after receiving the 2024 Prix Galien USA Award for Best Digital Health Startup, announced by the Company on November 12, 2024, and its advancement to the 2026 International competition reflects the structure of the Prix Galien International program, where eligibility is reserved for qualifying previous national and regional Prix Galien winners. The calibre of the broader 2026 nominee group, which includes products and technologies from global healthcare leaders such as AstraZeneca, Merck, Johnson & Johnson, Pfizer, Sanofi, Roche, Regeneron, Novo Nordisk, Gilead, Vertex and Medtronic, further underscores the significance of the recognition. Established in 1970, the Galien Foundation today operates through 16 chapters spanning more than 75 countries and describes the Prix Galien as widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

Schreibe Deinen Kommentar